The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: Virology, epidemiology, continental response, and research priorities.

Authors

Yi Zhang, Junkai Ren, Xuejun Ma, Xiaozhou He

Published in

Infectious medicine. Volume 5. Issue 3. Pages 100270. Epub Jun 25, 2026.

Abstract

Bundibugyo ebolavirus (BDBV), a member of the genus Orthoebolavirus, family Filoviridae, is hereafter referred to as Bundibugyo virus, with the associated illness termed Bundibugyo virus disease (BVD). First identified in Uganda in 2007, the virus has received far less scientific attention than the highly pathogenic Zaire ebolavirus. In April 2026, a cluster of unexplained deaths emerged in the mining-intensive Mongbwalu Health Zone of Ituri Province in the Democratic Republic of the Congo (DRC), and the causative agent was confirmed by whole-genome sequencing on 14 May 2026 as Bundibugyo virus. This is the DRC's 17th Ebola outbreak and only the third BVD epidemic globally. As of 10 June 2026, the DRC has reported 662 confirmed cases and 124 confirmed deaths, with the outbreak expanding across 25 health zones in Ituri, North Kivu, and South Kivu provinces; Uganda has reported 19 confirmed cases and 2 deaths. Unlike Zaire ebolavirus outbreaks, no licensed vaccine or specific therapeutic exists for BVD, and the response is further complicated by armed conflict, population mobility through mining corridors, fragile health systems, and community mistrust that has occasionally erupted into violence against responders. The World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) on 17 May 2026, and the Africa Centres for Disease Control and Prevention (Africa CDC) declared a Public Health Emergency of Continental Security (PHECS) on 18 May 2026. Under a unified "One Team, One Plan, One Budget, and One M&E Framework" architecture, the Africa Centres for Disease Control and Prevention and World Health Organization jointly issued the Bundibugyo Virus Disease Continental Preparedness and Response Plan, with a budget of $517.7 million over six months and structured around 14 technical pillars. This review provides a comprehensive synthesis of the virology, epidemiology, critical research gaps, and international response strategy, aiming to inform both ongoing outbreak operations and future scientific efforts.

PMID:
42434018
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.